BPC 157 Explained: Benefits, Safety & Oral vs Injectable Options The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA Peptide Reclassification 2026: What It Means for Providers When will the FDA reclassify BPC 157 to Category 1? Odds & Predictions